Stockreport

Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID [Yahoo! Finance]

Invivyd, Inc.  (IVVD) 
PDF versus placebo, at three months, from a single intramuscular (IM) dose, with protection beyond three months anticipated A second arm will evaluate monthly IM doses ver [Read more]